APPROXIMATELY 960 WILL BE RANDOMIZED AT APPROXIMATELY 100 CENTERS GLOBALLY. INFORMED CONSENT WILL BE OBTAINED FROM PATIENTS MEETING THE INCLUSION CRITERIA BEFORE THE INITIATION OF ANY STUDY-SPECIFIC P

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SINGLE-DOSE IV ORITAVANCIN VERSUS IV VANCOMYCIN FOR THE TREATMENT OF PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (SOLO I)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SINGLE-DOSE IV ORITAVANCIN VERSUS IV VANCOMYCIN FOR THE TREATMENT OF PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (SOLO I)